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Studies have suggested that, in subjects with subjective cognitive impairment (SCI), Alzheimer’s disease (AD)-like changes
may occur in the brain. Recently, an in vivo study has indicated the potential of ultra-high-field MRI to visualize amyloid-
beta (Aβ)-associated changes in the cortex in patients with AD, manifested by a phase shift on T2*-weighted MRI scans.
The main aim of this study was to investigate whether cortical phase shifts on T2*-weighted images at 7T in subjects with
SCI canbe detected, possibly implicating the deposition of Aβ plaques and associated iron. Cognitive tests and T2*-weighted
scans using a 7-T MRI system were performed in 28 patients with AD, 18 subjects with SCI and 27 healthy controls
(HCs). Cortical phase shifts were measured. Univariate general linear modeling and linear regression analysis were used
to assess the association between diagnosis and cortical phase shift, and between cortical phase shift and the different
neuropsychological tests, adjusted for age and gender. The phase shift (mean, 1.19; range, 1.00–1.35) of the entire cortex in
AD was higher than in both SCI (mean, 0.85; range, 0.73–0.99; p< 0.001) and HC (mean, 0.94; range, 0.79–1.10; p< 0.001).
NoAD-like changes, e.g. increased cortical phase shifts, were found in subjectswith SCI comparedwithHCs. In SCI, a significant
association was found between memory function (Wechsler Memory Scale, WMS) and cortical phase shift (β =–0.544,
p=0.007). The major finding of this study is that, in subjects with SCI, an increased cortical phase shift measured at high field
is associatedwith a poorermemory performance, although, as a group, subjects with SCI do not show an increased phase shift
comparedwithHCs. This increased cortical phase shift related tomemoryperformancemay contribute to theunderstandingof
SCI as it is still unclear whether SCI is a sign of pre-clinical AD. Copyright © 2014 John Wiley & Sons, Ltd.
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INTRODUCTION
Subjective cognitive impairment (SCI) is common in the elderly and
refers to a subjective decline in levels of cognitive functioning,
which cannot be confirmed by neuropsychological evaluation (1).
Longitudinal population-based studies have reported an associa-
tion with future cognitive decline (2) and dementia (3). Moreover,
neuroimaging studies have shown that, in subjects with SCI,
Alzheimer’s disease (AD)-like changes, such as loss of volume in
the medial temporal lobe and hippocampus, may have already oc-
curred before cognitive decline becomes evident (4–9). This sug-
gests that the elderly with SCI may be at risk for the development
of AD. Alternatively, cognitive complaints may be caused by other
factors, such as depression, anxiety and quality of life (10–13).
Recently, it has been demonstrated that T2*-weighted MRI at
high field provides indirect evidence of the presence of AD pa-
thology (14,15). This approach is based on the finding that, in au-
topsy material of patients with AD, amyloid-beta (Aβ) deposition
and neurofibrillary tangles (NFTs), as well as tau deficiency, are
found to co-localize with cortical iron accumulation (16–19).
Based on the high sensitivity of T2*-weighted MRI at 7 T in de-
tecting small cerebral iron deposits (20,21), we have shown in a
previous study that, in patients with AD, the magnitude of the
observed cortical phase shift in T2*-weighted phase images is
correlated with global cognitive functioning, and demonstrates
a high sensitivity in differentiating patients with AD from con-
trols (14). Based on the fact that Aβ plaques and NFTs occur up
to 10–20 years before cognitive decline can be measured (22),
and the findings that SCI predicts the future diagnosis of AD
(23,24), it could be hypothesized that, in subjects with SCI, differ-
ences in T2*-weighted cortical phase shifts may already be pres-
ent before cognitive decline can be determined.
The main aim of this study was to investigate whether cortical
phase shifts on T2*-weighted images at 7 T in subjects with SCI
can be detected, suggesting the deposition of Aβ plaques and asso-
ciated iron. The secondary aim was to investigate which cognitive
domains are associated with cortical phase shifts in these subjects.
MATERIALS AND METHODS
Participants
This study was approved by the local institutional review board.
In all cases, informed consent was obtained according to the
Declaration of Helsinki (25). In total, 28 patients with AD, with a
mean age of 71.2 years (range, 54–86 years; 18 men and 10
women), 18 subjects with SCI, with a mean age of 66.5 years
(range, 49–85 years; 13 men and five women), and 27 healthy
controls (HCs), with a mean age of 68.9 years (range, 52–80 years;
16 men and 11 women), were included.
Patients with AD and subjects with SCI were recruited from the
memory clinic of the Leiden University Medical Center, the VU
University Medical Center in Amsterdam, the Bronovo Hospital in
The Hague and the Diaconessen Hospital in Leiden. Memory clinic
patients were referred to the hospital by their general practitioner
or a medical specialist. Prior to the 7-T study, all patients
underwent a routine clinical protocol, comprising a whole-brain
clinical MRI and a battery of neuropsychological tests measuring
global cognitive functioning [Mini Mental State Examination
(MMSE) (26) and Cambridge Cognitive Examination (CAMCOG)
(27)], memory [Wechsler Memory Scale (WMS) (28) including digit
span forward and backward (working memory)], executive
function [Trail Making Test (TMT) part B (cognitive flexibility) (29)
and STROOP card 3 (inhibition) (30)], psychomotor speed [TMT part
A) (29)] and depression [abbreviated Geriatric Depression Scale
(GDS) (31)]. A general medical and neurological examination was
performed by a neurologist, psychiatrist or internist-geriatrician.
Diagnosis was made in a multidisciplinary consensus meeting
using the National Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria for the diagnosis of probable
AD (32). SCI was defined by the subjective feeling of memory
decline for which these subjects (based on memory complaints)
were referred to thememory clinic; however, subjects with SCI per-
formed within the normal range on standard neuropsychological
tests [i.e. criteria for mild cognitive impairment (MCI), dementia or
other neurologic or psychiatric disorder were not fulfilled]. Partici-
pants with the diagnosis ‘SCI’ and ‘probable AD’, whowere capable
of giving informed consent (MMSE≥ 19), were selected for
inclusion. Patients with AD and subjects with SCI were selected
for inclusion in the 7-T study either retrospectively within 1 year
after attending the memory clinic, or otherwise prospectively.
HCs were recruited as part of the Leiden Longevity Study, the
details of which have been described elsewhere (33). So as not to
predispose for familial longevity, only partners of offspring were
included. Subjects were included if they lived independently,
were aged ≤85 years, had a body mass index between 23 and
35 kg/m2, an MMSE ≥ 25 and a GDS ≤ 4. Individuals who were en-
gaged in heavy/intense physical activity, had been immobile for
longer than 1week in the preceding 3months, had shown psy-
chiatric or behavioral problems, or had used either thyroid med-
ication or immunosuppressants were excluded. Subjects were
screened for cognitive deficits by an internist-geriatrician, and
subjects with the following diseases were excluded: hemorrhagic
and ischemic stroke, Parkinson’s disease, dementia, MCI, diabe-
tes type I or II, rheumatoid arthritis, polymyalgia rheumatica, can-
cer, heart failure and chronic obstructive pulmonary disease.
Prior to the MRI scan, all subjects underwent cognitive testing,
measuring global cognitive functioning (MMSE), working mem-
ory (digit span forward and backward), executive function [TMT
part B (cognitive flexibility) and STROOP card 3 (inhibition)] and
psychomotor speed (TMT part A).
MRI
Image acquisition
MRI was performed on a whole-body, human, 7-T MRI system
(Philips Healthcare, Best, the Netherlands) using a quadrature
transmit and 16-channel receive head coil. Participants were
scanned using a two-dimensional, flow-compensated, transverse,
T2*-weighted gradient echo scan, including the frontal and parietal
regions, which are most prone to Aβ deposition, with a total imag-
ing duration of 10min. Positioning of this stack of slices was
planned within the frontal and parietal region above the occipital
lobe, using the sagittal plane of the survey scan as a reference.
The middle of the stack of slices was positioned through the cor-
pus callosum, just above the thalamus. Imaging parameters were
as follows: TR/TE= 1764/25ms; flip angle, 45°; slice thickness,
1.0mm with a 0.1-mm interslice gap; 20 slices; field of view,
240×180×22mm3; matrix size, 1024×768; in-plane spatial reso-
lution, 0.24× 0.24mm2. The bandwidth per pixel was 46Hz, corre-
sponding to a readout length of approximately 22ms. The
frequency- and phase-encoding directions were along the
anterior–posterior and right–left axes, respectively. Shimming up
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to third order was performed using an image-based shimming ap-
proach (34). The phase images were subsequently unwrapped by
high-pass filtering with a 92×92 kernel (35).
Image analysis
Phase values in the cortex were determined using the transverse
two-dimensional T2*-weighted gradient echo scans. The phase
values of the cortical gray matter (GM) were determined on the
unwrapped phase images in regions of interest (ROIs) in four
different areas of the brain: frontal, parietal, left temporoparietal
and right temporoparietal. Because of the laminar variation in
the cortical areas (36), histograms perpendicular to the cortex
within these regions were created to measure peak GM phase
values, over at least 10 cortical regions per slice and per region.
To correct for local macroscopic magnetic field inhomogeneities,
subcortical white matter (WM) phase values were measured
and used as an internal reference value. ROIs were selected con-
taining only the GM or WM, avoiding blood vessels, cerebrospi-
nal fluid (CSF), WM hyperintensities and other abnormalities
which could influence the results. Phase values for GM and
WMwere measured in these four areas per MRI slice for every
other slice (10 in total), resulting in 40 phase values for GM and
WM separately per subject. The phase values of the different
ROIs of the four regions were averaged. Per subject, the overall
phase shift between cortical GM and subcortical WM (lobar cor-
tical phase shift) was calculated for each region and expressed
in radians. All phase values reported in our article represent
these averages (14).
Statistics
Where appropriate, the data are expressed as the mean ± stan-
dard deviation. One-way analysis of variance (ANOVA) was used
to assess differences in age, phase shift measurements and
neuropsychological tests between patients with AD, subjects
with SCI and HCs. Post-hoc independent-samples t-tests were
used to assess differences in age, phase measurements and
different neuropsychological test results between groups (two-
sample comparison of means, two-sided test, equal variances
were assumed). To evaluate differences in gender and education,
chi-squared tests were performed. Univariate general linear
modeling analysis was used to assess the association between
diagnosis and cortical phase shifts, adjusted for age and gender.
To determine the association between the different neuropsy-
chological tests and phase shift in the cortex, linear regression
analysis was used, correcting for age and gender in subjects with
SCI. All statistical analyses were performed with the Statistical
Package of Social Sciences (SPSS, version 20.0; SPSS, Chicago,
IL, USA).
RESULTS
The characteristics of the participants, including the mean scores
for different neuropsychological tests per group, are shown in
Table 1. No differences in age, gender or education were found
between the groups. A small difference in performance on the
digit span backwards test (p = 0.024) and TMT part A (p =
0.042) between subjects with SCI and HCs was found. For the
other tests, no differences between these groups were found.
Patients with AD demonstrated an overall lower cognitive per-
formance than subjects with SCI and HCs.
Figure 1 shows representative magnitude and phase images
from a patient with AD, a subject with SCI and an HC. The mean
phase shift of the entire cortex in patients with AD (mean, 1.19;
range, 1.00–1.35) was higher than that for subjects with SCI
(mean, 0.85; range, 0.73–0.99; adjusted for age and gender, p <
0.001) and HCs (mean, 0.94; range, 0.79–1.10; adjusted for age
Table 1. Mean baseline characteristics, mean scores with standard deviation (SD) and range of different neuropsychological tests
of healthy controls (HC), subjects with subjective cognitive impairment (SCI) and patients with Alzheimer’s disease (AD). In addi-
tion, significant p values between the groups are shown
HC (SD; range) (n=27) SCI (SD; range) (n= 18) AD (SD; range) (n= 28)
Age (years) 68.9 (8.1; 52–80) 66.5 (11.2; 49–85) 71.2 (8.4; 54–86)
Male/female 16/11 13/5 18/10
Education (median) 3.3 (3) 3.5 (3) 4.0 (4)
GDS – 3.3 (2.6; 0–7) 3.3 (2.6; 0–9)
MMSE score 29.0 (1.1; 26–30) 28.3 (1.6; 25–30) 22.4 (2.0; 18–26)b,d
CAMCOG – 92.7 (5.0; 86–100) 74.5 (8.4; 50–87)d
WMS – 121.12 (15.2; 97–143) 91.1 (9.7; 74–103)d
Digit span forwards 5.8 (0.9; 5–7) 4.8 (0.8; 4–6) 5.2 (1.3; 3-8)
Digit span backwards 5.2 (1.0; 3–7) 3.8 (1.1; 2–5)a 3.6 (0.9; 2–5)b
TMT part A 35.0 (6.3; 28–46) 44.5 (15.9; 25–77)a 85.3 (80.4; 32–300)a,c
TMT part B 79.3 (25.9; 51–131) 100.5 (53.0; 44–208) 226.7 (90.4; 79–300)b,d
STROOP card 3 107.9 (31.6; 72–160) 132.3 (60.4; 83–300) 182.9 (70.2; 100–300)a
ap< 0.05 and
bp< 0.001: HC versus SCI or AD.
cp< 0.05 and
dp< 0.001: SCI versus AD.
CAMCOG, Cambridge Cognitive Examination; GDS, Geriatric Depression Scale; MMSE, Mini Mental State Examination; TMT, Trail
Making Test; WMS, Wechsler Memory Scale. TMT part A and B and STROOP card 3 are given in seconds; other
neuropsychological tests are given in points.
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and gender, p < 0.001). No AD-like changes, e.g. increased corti-
cal phase shifts, were found in subjects with SCI compared with
HCs. Parcellation into frontal, parietal and temporoparietal subre-
gions did not yield different conclusions.
Table 2 shows the results of the linear regression analysis ex-
amining the association between the cortical phase shift of the
whole brain (including all ROIs) and the scores of neuropsycho-
logical testing corrected for age and gender in subjects with
SCI. A significant association was found between memory func-
tion (WMS) and the cortical phase shift (β = –0.544, p = 0.007).
No significant association was found between other cognitive
functions and the cortical phase shift. Parcellation into frontal,
parietal and temporoparietal subregions showed a highly signifi-
cant association between the cortical phase shift in the frontal re-
gion in subjects with SCI andmemory function (WMS) (β = –0.721,
p < 0.0001), and a less significant association with global cogni-
tive functioning (MMSE) (β = –0.519, p = 0.021). Within the parie-
tal region, a less significant association was also found with
memory function (WMS) (β = –0.406, p = 0.041). It should be
noted that these results were not corrected for multiple compar-
isons and therefore should be interpreted with care, especially
those with moderate significance (i.e. 0.05–0.01).
Figure 1. Representative magnitude (a) and phase (including a scale bar in hertz) (b) images acquired from a patient with Alzheimer’s disease (1), a
subject with subjective cognitive impairment (2) and a healthy control (3).
Table 2. β and p values correlating cortical phase shift with the scores of neuropsychological testing in subjects with subjective
cognitive impairment, adjusted for age and gender
Cognitive domain Cognitive test
β Std. error B Partial r P value
Depression GDS –0.007 0.014 –0.009 0.991
Global cognitive functioning MMSE –0.238 0.011 –0.278 0.297
Global cognitive functioning CAMCOG –0.251 0.004 –0.300 0.320
Memory WMS –0.544 0.001 –0.667 0.007*
Psychomotor speed TMT part A 0.616 0.002 0.445 0.096
Executive function (cognitive flexibility) TMT part B 0.250 0.001 0.171 0.541
Executive function (inhibition) STROOP card 3 –0.060 0.000 –0.068 0.863
CAMCOG, Cambridge Cognitive Examination; GDS, Geriatric Depression Scale; MMSE, Mini Mental State Examination; TMT, Trail
Making Test; WMS, Wechsler Memory Scale.
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DISCUSSION
The major finding of this study is that, in subjects with SCI, an in-
creased cortical phase shift measured with high-field MRI is asso-
ciated with a poorer memory performance, although, as a group,
subjects with SCI did not show an increased phase shift com-
pared with HCs. The finding of an increased cortical phase shift
being related to memory performance is important new infor-
mation, as it is still unclear whether SCI represents a first stage
of AD or a sign of pre-clinical AD, and results from previous stud-
ies are inconclusive with regard to the rate of decline and risk for
conversion to AD dementia (1). Previous longitudinal and epide-
miological studies have suggested that SCI is a precursor of AD
(3,37,38), and therefore we hypothesized that we might find an
increased phase shift, related to AD pathology, in subjects with
SCI compared with controls, but that this phase shift would be
lower relative to that of patients with AD. However, we did not
find an increased cortical phase shift in subjects with SCI com-
pared with HCs. Our findings might be explained by studies
demonstrating that the majority of subjects with SCI do not de-
velop AD, as there is only a 20% chance that SCI will progress
to dementia in this group (39), and multiple factors contribute
to the presence of cognitive complaints, such as depression, anx-
iety and quality of life (11–13). Moreover, SCI is a heterogeneous
group in which some pre-AD subjects might show an increase in
phase, whereas non-AD cognitive impairment is associated with
a phase decrease, perhaps suggesting a different mechanism for
this group.
Our study shows that the cortical phase shift, determined on
T2*-weighted MRI at 7 T, is associated with memory performance
in subjects with SCI. In contrast, global cognition, executive func-
tion and psychomotor speed are not associated with the cortical
phase shift in these subjects. Based on previous studies, we ex-
pected to find an association between the iron-sensitive phase
shift and cognition (40). However, assuming that the cortical
phase shift is an indirect marker of the amount of amyloid
plaques, the association would be more complicated. Previous
studies have shown that this association is not straightforward
and is most probably influenced by the presence of NFTs, as
discussed in a review by Nelson et al. (22). The dynamic bio-
markers model of AD states that AD starts with an increase in
Aβ in the brain, followed by the formation of NFTs and, at a later
stage, memory is impaired when the amount of Aβ is still increas-
ing (41). As we found an association between the cortical phase
shift and memory, and no other cognitive domain, this implies
that, in subjects with SCI, the cortical phase shift might be a
marker to demonstrate very early changes in the brain related
to memory function.
Our data demonstrate that subjects with SCI do not show AD-
like phase changes in comparison with HCs. Although the SCI
group performs slightly lower on the cognitive tests than the
HC group, our results also show no highly significant differences
in cognitive function between the groups. Several explanations
for these findings are possible and are partly described above.
If SCI is indeed an early AD stage, in which AD pathology is pres-
ent without the presence of cognitive symptoms, as suggested
by several studies, our data indicate that phase changes would
only appear at a later stage of the disease when AD pathology
is more severe and starts to have an effect on brain function. An-
other explanation for our results might be that SCI is not strongly
associated with AD, as it is related to many factors other than AD,
and only a small subset of the subjects with SCI develop AD
(10–13,42). Alternatively, because phase changes are measured
at a group level, it might be that, as most subjects with SCI do
not develop AD, the differences between controls and subjects
with SCI are too small to be significant. The investigation of
cortical phase changes in longitudinal studies in subjects with
SCI, MCI and AD to evaluate the possibility of detecting early
AD pathology over time could provide more insight into SCI
and the development of AD pathology, and the association
with cortical phase changes and cognitive performance.
One overall limitation of this study is that phase measure-
ments may partly be influenced by the geometry and orientation
of the individual structures (21). To limit these effects as much as
possible, all participants were positioned in the same manner
and, for every subject, the phase measurements were performed
in the same way and were averaged to cancel out the possible
effects of geometry and orientation. Although it is most likely
that the difference in phase shift between groups is mainly attrib-
utable to iron, other compounds may contribute to a change in
phase shift, such as deoxyhemoglobin, myelin and proteins (36,43).
In conclusion, in this study, we have shown that patients with
AD demonstrate an increased cortical phase shift, indicating
greater iron accumulation, compared with HCs. Moreover, these
cortical phase shifts are associated with decreased memory per-
formance in subjects with SCI. Although previous studies have
suggested that, in SCI, AD-like changes may occur before cogni-
tive decline becomes manifest, our data do not show any signs
of AD-like high-field T2*-weighted cortical phase shifts at a group
level in subjects with SCI.
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